e-Drug3D

2073

FEZOLINETANT

INN
FEZOLINETANT

cas 1629229-37-3

CLASS

GENITO
NEUROKININ 3 (NK3) RECEPTOR ANTAGONIST
TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE

ROUTE (list)

ORAL

ATC code

G02CX06

PK parameters

Tmax 1.5 HOUR
VD 189 LITER
Cl 10.8 LITER / HOUR
PPB 51 PERCENT
t1/2 9.6 HOUR

Solubility

VERY SLIGHTLY SOLUBLE IN WATER (0.29 MILLIGRAM PER MILLILITER)

Target

TARGET NEUROKININ 3 (NK3) RECEPTOR

Neuromedin-K receptor UNIPROT P29371

Download SDF file

Methanone, [(8R)-5,6-dihydro-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl](4-fluorophenyl)- (ACI)

Formula:
C16H15FN6OS

Calculated chemical properties:

MW 358.41
NB_atoms 25
XLogP 2.46
PSA 66.783
NB_HD 0
NB_HA 7
fsp3 0.31
Lipinski(0=no;1=yes) 1

FDA
NDA 216578 (label) INN (FEZOLINETANT) VEOZAH (ASTELLAS) APPROVAL= AP YEAR= 2023 NEWMOLECULARENTITY